Available Across the UK
UK-based Clinical Support
MHRA-registered Devices
No Consumables Needed
Turn Clinical Evidence Into Practice Growth with Aerolase
Whether you're clearing acne, treating melasma and PIH, managing rosacea, or resurfacing scarred skin — Aerolase delivers consistent, clinically proven outcomes across every Fitzpatrick skin type. One platform. No consumables. Built for the full range of patients walking through your door.

Clinical Evidence — Physician-reported
Proven results in skin rejuvenation and blemish clearance1
Physicians reported improvement in acne scars2
Physicians report improvement in PIH or erythema2
Practice Performance
Patient satisfaction rate
Leader in treating all skin types safely
1 Saedi N, Griffin T Jr, Kelly S. Treatment of mild to severe acne vulgaris with a 650-microsecond 1064-nm Nd:YAG laser. J Drugs Dermatol. 2021;20(9):1000-1004.
2 “Response of Acne Patients to Treatment with a 650-Microsecond, 1064-nm, Pulsed Nd:YAG Laser: A Survey of 50 Dermatologists.” Surg Med, 56: S5-S185.
See these outcomes in your own clinic.
Join dermatologists and aesthetic practitioners already using Aerolase to treat every patient, every skin tone, year-round.
Plastic Surgery
Aerolase provides the precision needed to enhance both surgical and non-surgical aesthetic outcomes. The technology serves as both a standalone treatment and a powerful adjunct to surgical procedures such as: Post-surgical scars, rhinoplasty, skin tightening, and post-op hyperpigmentation.
Dentistry
Dental practices understand that exceptional smile aesthetics extend beyond the teeth and gums to encompass the entire perioral and facial region. Aerolase technology enables dentists to deliver complete aesthetic solutions that address both oral and facial concerns with the ability to combine with injectable treatments.
Medical Aesthetics
The aesthetic landscape demands technology that can address increasingly complex patient expectations while navigating diverse skin types without compromising safety or comfort. Aerolase provides the clinical versatility and proven outcomes needed to build thriving aesthetic practices.
Clear Acne, Brighten Pigment, Tighten Skin—All in One Device
The Neo Elite’s® high-powered, 1064nm Nd:YAG laser, backed by advanced 650-microsecond technology, allows you to address acne, melasma, rosacea, PIH, and more—making it ideal for growing practices seeking both clinical excellence and operational efficiency.
• No topicals. No consumables. No cooling — fewer overheads, more margin per treatment.
• Safe across Fitzpatrick I–VI — treat every patient without protocol modification.
• Clinically proven to outperform traditional Nd:YAG systems for acne, melasma, and PIH.
Medical Indications:
Aesthetic Indications:


Treat Scars, Wrinkles & Texture Safely—Without Numbing or Cooling
Era Elite® is the answer to ablative resurfacing—powerful enough to correct deep scars and fine lines, yet gentle enough for any skin tone. Unlike traditional CO2 lasers, the Era’s 2940nm precision and a 300-microsecond pulse adapts to your patient's needs—delivering full-field or fractional treatments with high safety and minimal recovery.
• Layer-by-layer scar revision without damaging surrounding tissue — and without the 2-week CO2 recovery.
• Demonstrated increase in collagen synthesis — measurable improvement in scar depth and skin elasticity.
• 3–5 day downtime. Suitable for all skin tones. No topical anaesthesia required.
Aesthetic Indications:
Exci308® by Aerolase sets a new standard for excimer technology. Engineered for best-in-class performance, it surpasses other excimer devices across every key metric — including affordability, compact design, treatment speed, and ease of use. Exci308® delivers the same high-level clinical efficacy for autoimmune skin conditions with faster treatment sessions and a more streamlined experience for both patients and providers.
Autoimmune conditions treated with the Exci308:

Testimonials



Book Your 30-Minute Clinical Demo.
Find out what Neo Elite and Era Elite can do for your clinic and your patients.

















